Neural mechanisms underlying peak-dose d
✍
Susan H. Fox; Brian Henry; Micheal P. Hill; David Peggs; Alan R. Crossman; Jonat
📂
Article
📅
2001
🏛
John Wiley and Sons
🌐
English
⚖ 102 KB
## Abstract Dyskinesia, secondary to dopamine replacement therapy, is the major complication of currently available therapies for Parkinson's disease. Alpha~2~ adrenoceptor antagonists, such as idazoxan, can significantly reduce levodopa‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydr